High Growth Tech Stocks In Hong Kong October 2024

In This Article:

As geopolitical tensions and economic uncertainties weigh on global markets, the Hong Kong tech sector has shown resilience, with the Hang Seng Index climbing 10.2% amid optimism about China's supportive measures. In this environment, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation capabilities and adaptability to shifting market dynamics, which are crucial in navigating the current landscape.

Top 10 High Growth Tech Companies In Hong Kong

Name

Revenue Growth

Earnings Growth

Growth Rating

Wasion Holdings

22.37%

25.47%

★★★★★☆

MedSci Healthcare Holdings

48.74%

48.78%

★★★★★☆

Inspur Digital Enterprise Technology

25.31%

39.04%

★★★★★☆

RemeGen

26.30%

52.19%

★★★★★☆

Innovent Biologics

21.80%

59.60%

★★★★★☆

Akeso

33.30%

53.00%

★★★★★★

Cowell e Holdings

31.68%

35.44%

★★★★★★

Biocytogen Pharmaceuticals (Beijing)

21.53%

109.17%

★★★★★☆

Beijing Airdoc Technology

37.47%

93.35%

★★★★★☆

Sichuan Kelun-Biotech Biopharmaceutical

24.70%

8.53%

★★★★★☆

Click here to see the full list of 43 stocks from our SEHK High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Innovent Biologics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibodies and other drug assets for various diseases in China, with a market cap of approximately HK$79.68 billion.

Operations: Innovent Biologics generates revenue primarily from its biotechnology segment, amounting to CN¥7.46 billion. The company focuses on developing and commercializing treatments for oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in China.

Innovent Biologics, a dynamic player in the biotech sector, is making significant strides with its recent strategic collaboration for limertinib's commercialization in China, promising to enhance its market presence. This move aligns with Innovent’s robust R&D focus where it allocated 21.8% of its revenue last year towards research initiatives. Notably, the company is poised for rapid growth with projected annual revenue increases of 21.8% and earnings expected to surge by 59.6%. Such financial commitment to innovation underscores Innovent's potential to capitalize on emerging opportunities within the high-stakes biopharmaceutical landscape in Asia and beyond.

SEHK:1801 Revenue and Expenses Breakdown as at Oct 2024
SEHK:1801 Revenue and Expenses Breakdown as at Oct 2024

BYD Electronic (International)

Simply Wall St Growth Rating: ★★★★☆☆